{"title":"Beyond Survival: Empowering Women by Enhancing Reproductive Health Education for Heart Transplant Recipients.","authors":"Sophia Airhart, Catriona Bhagra","doi":"10.1161/CIRCHEARTFAILURE.124.012085","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.012085","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e012085"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Catherine G Ireland, Danielle S Burstein, Sharlene M Day, Anna Axelsson Raja, Mark W Russell, Kenneth G Zahka, Alexandre Pereira, Charles E Canter, Richard G Bach, Matthew T Wheeler, Joseph W Rossano, Anjali T Owens, Henning Bundgaard, Luisa Mestroni, Matthew R G Taylor, Amit R Patel, Ivan Wilmot, Jonathan H Soslow, Jason R Becker, Ilya Giverts, E John Orav, Brian Claggett, Kimberly Y Lin, Carolyn Y Ho
{"title":"Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.","authors":"Catherine G Ireland, Danielle S Burstein, Sharlene M Day, Anna Axelsson Raja, Mark W Russell, Kenneth G Zahka, Alexandre Pereira, Charles E Canter, Richard G Bach, Matthew T Wheeler, Joseph W Rossano, Anjali T Owens, Henning Bundgaard, Luisa Mestroni, Matthew R G Taylor, Amit R Patel, Ivan Wilmot, Jonathan H Soslow, Jason R Becker, Ilya Giverts, E John Orav, Brian Claggett, Kimberly Y Lin, Carolyn Y Ho","doi":"10.1161/CIRCHEARTFAILURE.124.011663","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011663","url":null,"abstract":"<p><strong>Background: </strong>The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being.</p><p><strong>Methods: </strong>VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) participants with early stage sarcomeric HCM (primary analysis cohort) and subclinical HCM (sarcomere variant without left ventricular hypertrophy comprising the exploratory cohort) who completed baseline and year 2 HRQOL assessment via the pediatric quality of life inventory and CPET were studied. Metrics correlating with baseline HRQOL and CPET performance were identified. The impact of valsartan treatment on these measures was analyzed in the early stage cohort.</p><p><strong>Results: </strong>Two hundred participants were included: 166 with early stage HCM (mean age, 23±10 years; 40% female; 97% White; and 92% New York Heart Association class I) and 34 subclinical sarcomere variant carriers (mean age, 16±5 years; 50% female; and 100% White). Baseline HRQOL was good in both cohorts, although slightly better in subclinical HCM (composite pediatric quality of life score 84.6±10.6 versus 90.2±9.8; <i>P</i>=0.005). Both cohorts demonstrated mildly reduced functional status (mean percent predicted peak oxygen uptake 73±16 versus 78±12 mL/kg per minute; <i>P</i>=0.18). Percent predicted peak oxygen uptake and peak oxygen pulse correlated with HRQOL. Valsartan improved physical HRQOL in early stage HCM (adjusted mean change in pediatric quality of life score +4.1 versus placebo; <i>P</i>=0.01) but did not significantly impact CPET performance.</p><p><strong>Conclusions: </strong>Functional capacity can be impaired in young, healthy people with early stage HCM, despite New York Heart Association class I status and good HRQOL. Peak oxygen uptake was similarly decreased in subclinical HCM despite normal left ventricular wall thickness and excellent HRQOL. Valsartan improved physical pediatric quality of life scores but did not significantly impact CPET performance. Further studies are needed for validation and to understand how to improve patient experience.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT01912534.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011663"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Circulation: Heart FailurePub Date : 2024-08-01Epub Date: 2024-08-09DOI: 10.1161/CIRCHEARTFAILURE.124.011569
W H Wilson Tang, Rozenn N Lemaitre, Paul N Jensen, Meng Wang, Zeneng Wang, Xinmin S Li, Ina Nemet, Yujin Lee, Heidi T M Lai, Marcia C de Oliveira Otto, Amanda M Fretts, Nona Sotoodehnia, Joseph A DiDonato, Fredrik Bäckhed, Bruce M Psaty, David S Siscovick, Matthew J Budoff, Dariush Mozaffarian, Stanley L Hazen
{"title":"Trimethylamine <i>N</i>-Oxide and Related Gut Microbe-Derived Metabolites and Incident Heart Failure Development in Community-Based Populations.","authors":"W H Wilson Tang, Rozenn N Lemaitre, Paul N Jensen, Meng Wang, Zeneng Wang, Xinmin S Li, Ina Nemet, Yujin Lee, Heidi T M Lai, Marcia C de Oliveira Otto, Amanda M Fretts, Nona Sotoodehnia, Joseph A DiDonato, Fredrik Bäckhed, Bruce M Psaty, David S Siscovick, Matthew J Budoff, Dariush Mozaffarian, Stanley L Hazen","doi":"10.1161/CIRCHEARTFAILURE.124.011569","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011569","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence indicates that trimethylamine <i>N</i>-oxide, a gut microbial metabolite of dietary choline and carnitine, promotes both cardiovascular disease and chronic kidney disease risk. It remains unclear how circulating concentrations of trimethylamine <i>N</i>-oxide and its related dietary and gut microbe-derived metabolites (choline, betaine, carnitine, γ-butyrobetaine, and crotonobetaine) affect incident heart failure (HF).</p><p><strong>Methods: </strong>We evaluated 11 768 participants from the Cardiovascular Health Study and the Multi-Ethnic Study of Atherosclerosis with serial measures of metabolites. Cox proportional hazard models were used to examine the associations between metabolites and incident HF, adjusted for cardiovascular disease risk factors.</p><p><strong>Results: </strong>In all, 2102 cases of HF occurred over a median follow-up of 15.9 years. After adjusting for traditional risk factors, higher concentrations of trimethylamine <i>N</i>-oxide (hazard ratio, 1.15 [95% CI, 1.09-1.20]; <i>P</i><0.001), choline (hazard ratio, 1.44 [95% CI, 1.26-1.64]; <i>P</i><0.001), and crotonobetaine (hazard ratio, 1.24 [95% CI, 1.16-1.32]; <i>P</i><0.001) were associated with increased risk for incident HF. After further adjustment for renal function (potential confounder or mediator), these associations did not reach Bonferroni-corrected statistical significance (<i>P</i>=0.01, 0.049, and 0.006, respectively). Betaine and carnitine were nominally associated with a higher incidence of HF (<i>P</i><0.05). In exploratory analyses, results were similar for subtypes of HF based on left ventricular ejection fraction, and associations appeared generally stronger among Black and Hispanic/Latino versus White adults, although there were no interactions for any metabolites with race.</p><p><strong>Conclusions: </strong>In this pooled analysis of 2 well-phenotyped, diverse, community-based cohorts, circulating concentrations of gut microbe-derived metabolites such as trimethylamine <i>N</i>-oxide, choline, and crotonobetaine were independently associated with a higher risk of developing HF.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov/; Unique identifiers: NCT00005133 and NCT00005487.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011569"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Circulation: Heart FailurePub Date : 2024-08-01Epub Date: 2024-07-25DOI: 10.1161/CIRCHEARTFAILURE.124.011568
Jane T Kelleher, Michael M Givertz
{"title":"Antithrombotic Therapy for Mechanical Circulatory Support: Time to Throw the Baby (Warfarin) Out With the Bathwater (Aspirin)?","authors":"Jane T Kelleher, Michael M Givertz","doi":"10.1161/CIRCHEARTFAILURE.124.011568","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011568","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011568"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Circulation: Heart FailurePub Date : 2024-07-01Epub Date: 2024-06-20DOI: 10.1161/CIRCHEARTFAILURE.124.011678
Amrin Kharawala, Sanjana Nagraj, Jiyoung Seo, Sumant Pargaonkar, Mayuko Uehara, Daniel J Goldstein, Snehal R Patel, Daniel B Sims, Ulrich P Jorde
{"title":"Donation After Circulatory Death Heart Transplant: Current State and Future Directions.","authors":"Amrin Kharawala, Sanjana Nagraj, Jiyoung Seo, Sumant Pargaonkar, Mayuko Uehara, Daniel J Goldstein, Snehal R Patel, Daniel B Sims, Ulrich P Jorde","doi":"10.1161/CIRCHEARTFAILURE.124.011678","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011678","url":null,"abstract":"<p><p>Orthotopic heart transplant is the gold standard therapeutic intervention for patients with end-stage heart failure. Conventionally, heart transplant has relied on donation after brain death for organ recovery. Donation after circulatory death (DCD) is the donation of the heart after confirming that circulatory function has irreversibly ceased. DCD-orthotopic heart transplant differs from donation after brain death-orthotopic heart transplant in ways that carry implications for widespread adoption, including differences in organ recovery, storage and ethical considerations surrounding normothermic regional perfusion with DCD. Despite these differences, DCD has shown promising early outcomes, augmenting the donor pool and allowing more individuals to benefit from orthotopic heart transplant. This review aims to present the current state and future trajectory of DCD-heart transplant, examine key differences between DCD and donation after brain death, including clinical experiences and innovations in methodologies, and address the ongoing ethical challenges surrounding the new frontier in heart transplant with DCD donors.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011678"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Circulation: Heart FailurePub Date : 2024-07-01Epub Date: 2024-06-24DOI: 10.1161/CIRCHEARTFAILURE.123.011504
Mengda Xu, Hang Zhang, Yuan Chang, Xiumeng Hua, Xiao Chen, Yixuan Sheng, Dan Shan, Mengni Bao, Shengshou Hu, Jiangping Song
{"title":"Overexpression of <i>ATP5F1A</i> in Cardiomyocytes Promotes Cardiac Reverse Remodeling.","authors":"Mengda Xu, Hang Zhang, Yuan Chang, Xiumeng Hua, Xiao Chen, Yixuan Sheng, Dan Shan, Mengni Bao, Shengshou Hu, Jiangping Song","doi":"10.1161/CIRCHEARTFAILURE.123.011504","DOIUrl":"10.1161/CIRCHEARTFAILURE.123.011504","url":null,"abstract":"<p><strong>Background: </strong>The mechanism of cardiac reverse remodeling (CRR) mediated by the left ventricular assist device remains unclear. This study aims to identify the specific cell type responsible for CRR and develop the therapeutic target that promotes CRR.</p><p><strong>Methods: </strong>The nuclei were extracted from the left ventricular tissue of 4 normal controls, 4 CRR patients, and 4 no cardiac reverse remodeling patients and then subjected to single-nucleus RNA sequencing for identifying key cell types responsible for CRR. Gene overexpression in transverse aortic constriction and dilated cardiomyopathy heart failure mouse model (C57BL/6J background) and pathological staining were performed to validate the results of single-nucleus RNA sequencing.</p><p><strong>Results: </strong>Ten cell types were identified among 126 156 nuclei. Cardiomyocytes in CRR patients expressed higher levels of <i>ATP5F1A</i> than the other 2 groups. The macrophages in CRR patients expressed more anti-inflammatory genes and functioned in angiogenesis. Endothelial cells that elevated in no cardiac reverse remodeling patients were involved in the inflammatory response. Echocardiography showed that overexpressing <i>ATP5F1A</i> through cardiomyocyte-specific adeno-associated virus 9 demonstrated an ability to improve heart function and morphology. Pathological staining showed that overexpressing <i>ATP5F1A</i> could reduce fibrosis and cardiomyocyte size in the heart failure mouse model.</p><p><strong>Conclusions: </strong>The present results of single-nucleus RNA sequencing and heart failure mouse model indicated that <i>ATP5F1A</i> could mediate CRR and supported the development of therapeutics for overexpressing <i>ATP5F1A</i> in promoting CRR.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011504"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11244755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Circulation: Heart FailurePub Date : 2024-07-01Epub Date: 2024-06-24DOI: 10.1161/CIRCHEARTFAILURE.124.011874
Martha Abshire Saylor, Colleen K McIlvennan
{"title":"SUSTAINing the Care of Patients With Advanced Heart Failure by Supporting Family Caregivers.","authors":"Martha Abshire Saylor, Colleen K McIlvennan","doi":"10.1161/CIRCHEARTFAILURE.124.011874","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011874","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011874"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Circulation: Heart FailurePub Date : 2024-07-01Epub Date: 2024-06-20DOI: 10.1161/CIRCHEARTFAILURE.124.011970
Sanne Ten Berg, Luuk Otterspoor, José P S Henriques
{"title":"Letter by ten Berg et al Regarding Article, \"Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry\".","authors":"Sanne Ten Berg, Luuk Otterspoor, José P S Henriques","doi":"10.1161/CIRCHEARTFAILURE.124.011970","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011970","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011970"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}